WEE1 and glioma: For example, Dasatinib, a small-molecule tyrosine kinase inhibitor, has been shown in vitro to effectively suppress the malignant phenotype of glioma stem cells when combined with a WEE1 inhibitor, and it exhibited higher predicted sensitivity in the high-risk group [45].